For centuries, American state governance saw a steady, pragmatic expansion of gubernatorial emergency powers, establishing the governor as the primary crisis manager in the federal system. This long-standing tradition reached its zenith during the COVID-19 pandemic when all fifty governors deployed sweeping emergency measures. Yet this unprecedented exercise of executive power triggered an equally unprecedented legislative backlash. In many states, legislatures systematically stripped governors of emergency authorities that had evolved over generations. This Article argues this was not a thoughtful recalibration but a historically shortsighted, constitutionally suspect, and dangerous overcorrection.

First, it demonstrates that executive emergency authority was the product of deliberate accumulation over two centuries. Second, it argues that the recent legislative reforms are constitutionally flawed, violating core separation of powers principles by enabling legislative micromanagement of executive functions and, in many states, empowering gerrymandered, minoritarian legislatures to subvert the will of statewide majorities. These changes create a perilous mismatch between institutional capacity and crisis demands by shifting authority to deliberative bodies inherently ill-suited for emergency response.

When the next disaster strikes, governors will find emergency declarations expiring, federal aid jeopardized, and response capabilities fragmented. This legislative assault—often amounting to institutional revenge that conflates policy disagreements with constitutional crises—sacrifices public safety for partisan advantage. The Article proposes balanced reforms that preserve executive flexibility while ensuring democratic accountability.

This article examines the U.S. government's aggressive and novel legal strategies in prosecuting pharmaceutical and medical device manufacturers for the off-label promotion of approved products. The authors highlight a fundamental tension between these enforcement actions and the public interest in disseminating scientific information about off-label uses, which are often a vital component of medical practice. The primary legal tool for these prosecutions has been the False Claims Act (FCA), frequently initiated by whistle-blower (qui tam) lawsuits alleging that off-label promotion induces fraudulent claims to government healthcare programs like Medicare and Medicaid. While civil actions under the FCA can result in substantial fines, the government often pursues parallel criminal investigations under the Federal Food, Drug, and Cosmetic Act (FDCA) to leverage more severe penalties. The article details the two main criminal prosecution theories under the FDCA: unapproved "new drug" theory and misbranding theory. The authors also explore the significant First Amendment implications of regulating the dissemination of truthful, non-misleading information about off-label uses. The article provides in-depth analysis of the factual patterns that trigger government investigations with examples from prominent cases. Key areas of focus for investigators include sales data, business and marketing plans, and sales force conduct. Despite the legal ambiguity and untested nature of its prosecution theories, the government has achieved significant financial settlements. The article suggests that future legal clarity may emerge from criminal or civil cases where the government declines to intervene (where vigorous challenge of the government's legal theories most likely).